Orexin and sleep quality in anorexia nervosa: Clinical relevance and influence on treatment outcome
Impacto
Scholar |
Otros documentos de la autoría: Sauchelli, Sarah; Jiménez-Murcia, Susana; Sánchez, Isabel; Riesco, Nadine; Custal, Nuria; Fernández García, José Carlos; Garrido-Sánchez, Lourdes; Tinahones Madueño, Francisco Javier; Steiger, Howard; Israel, Mimi; Baños, Rosa Maria; Botella, Cristina; De la Torre, Rafael; Fernández-Real, José Manuel; Ortega, Francisco J.; Frühbeck, Gema; Granero, Roser; Tárrega, Salomé; Crujeiras, Ana B.; Rodríguez, Amaia; Estivill, Xavier; Beckmann, Jacques S.; Casanueva, Felipe F.
Metadatos
Mostrar el registro completo del ítemcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/8033
comunitat-uji-handle3:10234/8636
comunitat-uji-handle4:
INVESTIGACIONEste recurso está restringido
http://dx.doi.org/10.1016/j.psyneuen.2015.12.014 |
Metadatos
Título
Orexin and sleep quality in anorexia nervosa: Clinical relevance and influence on treatment outcomeAutoría
Fecha de publicación
2016Editor
ElsevierISSN
0306-4530; 1873-3360Tipo de documento
info:eu-repo/semantics/articleVersión de la editorial
http://www.sciencedirect.com/science/article/pii/S030645301530038XPalabras clave / Materias
Resumen
Background and aims
Orexins/hypocretins are orexigenic peptides implicated in the regulation of feeding behavior and the sleep/wake cycle. Little is known about the functioning of these peptides in anorexia nervosa ... [+]
Background and aims
Orexins/hypocretins are orexigenic peptides implicated in the regulation of feeding behavior and the sleep/wake cycle. Little is known about the functioning of these peptides in anorexia nervosa (AN). The aims of the current study were to evaluate the extent to which orexin-A might be linked to sleep and treatment outcome in AN.
Method
Fasting plasma orexin-A concentrations were measured in 48 females with AN at the start of a day hospital treatment and in 98 normal-eater/healthy-weight controls. The Pittsburgh Sleep Quality Index was administered at the beginning of the treatment as a measure of sleep quality. Other psychopathological variables were evaluated with the Symptom Checklist-Revised (SCL90R) and the Eating Disorder Inventory-2 (EDI). Patients were assessed at the start and end of treatment by means of commonly used diagnostic criteria and clinical questionnaires.
Results
The AN patients presented more sleep disturbances and poorer overall sleep quality than did the healthy controls (p = .026) but there were no global differences between groups in plasma orexin-A concentrations (p = .071). In the AN sample, orexin-A concentrations were associated with greater sleep disturbances (|r| = .30), sleep inefficiency (|r| = .22) and poorer overall sleep (|r| = .22). Structural Equation Modeling (SEM) showed that both elevated orexin-A concentrations and inadequate sleep predicted poorer treatment outcome.
Conclusion
Plasma orexin-A concentrations contribute to poor sleep quality in AN, and both of these variables are associated with therapy response. [-]
Publicado en
Psychoneuroendocrinology, 2016, vol. 65Derechos de acceso
©
2015
Elsevier
Ltd.
All
rights
reserved.
http://rightsstatements.org/vocab/InC/1.0/
info:eu-repo/semantics/restrictedAccess
http://rightsstatements.org/vocab/InC/1.0/
info:eu-repo/semantics/restrictedAccess
Aparece en las colecciones
- PSB_Articles [1330]